Compugen Ltd
NASDAQ:CGEN
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IL |
|
Compugen Ltd
NASDAQ:CGEN
|
169.3m USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
213.3B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.5B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81.6T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.5B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
273.1B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.5B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.9B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.6B USD |
Loading...
|
Market Distribution
| Min | -85 210% |
| 30th Percentile | -8.6% |
| Median | 1.8% |
| 70th Percentile | 7.2% |
| Max | 23 652.1% |
Other Profitability Ratios
Compugen Ltd
Glance View
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Compugen Ltd is -400.1%, which is below its 3-year median of -183.9%.
Over the last 3 years, Compugen Ltd’s Net Margin has increased from -449.2% to -400.1%. During this period, it reached a low of -449.2% on Dec 31, 2022 and a high of 2.7% on Sep 30, 2024.
